Work

Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.7504

Authors: Ranjana H. Advani, Ian Flinn, Leslie Popplewell, Andres Forero-Torres, Nancy L. Bartlett, Nilanjan Ghosh, Justin Paul Kline, Thu Tran, Judith Lynn, James Y Chen, Balaji Agoram, Jenny Huang, Chris H.M. Takimoto, Mark Chao, Sonali M. Smith

Institutions: Stanford Cancer Institute, Sarah Cannon, City Of Hope National Medical Center, University of Alabama at Birmingham, Washington University in St. Louis, Carolinas Healthcare System, University of Chicago, Stanford Medicine, Stanford University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890332178

Cites:

Cited by: 24

Related to: 10